Rice Hall James & Associates LLC boosted its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 1.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,903 shares of the biopharmaceutical company’s stock after buying an additional 279 shares during the period. Rice Hall James & Associates LLC’s holdings in Vanda Pharmaceuticals were worth $455,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently modified their holdings of the stock. Point72 Asset Management L.P. raised its position in shares of Vanda Pharmaceuticals by 1,544.3% in the first quarter. Point72 Asset Management L.P. now owns 2,484,500 shares of the biopharmaceutical company’s stock worth $34,783,000 after buying an additional 2,333,400 shares during the last quarter. FMR LLC increased its stake in shares of Vanda Pharmaceuticals by 60.7% in the first quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock worth $22,416,000 after buying an additional 604,900 shares during the period. Vanguard Group Inc. increased its stake in shares of Vanda Pharmaceuticals by 26.4% in the first quarter. Vanguard Group Inc. now owns 2,494,347 shares of the biopharmaceutical company’s stock worth $34,920,000 after buying an additional 521,669 shares during the period. Nexthera Capital LP bought a new stake in shares of Vanda Pharmaceuticals during the first quarter worth approximately $7,171,000. Finally, Renaissance Technologies LLC increased its stake in shares of Vanda Pharmaceuticals by 65.3% in the first quarter. Renaissance Technologies LLC now owns 939,250 shares of the biopharmaceutical company’s stock worth $13,150,000 after buying an additional 370,900 shares during the period. 90.84% of the stock is owned by hedge funds and other institutional investors.

Shares of Vanda Pharmaceuticals Inc. (VNDA) opened at 16.25 on Wednesday. The stock’s market cap is $728.94 million. The stock has a 50 day moving average price of $16.18 and a 200-day moving average price of $14.76. Vanda Pharmaceuticals Inc. has a 12-month low of $11.58 and a 12-month high of $18.00.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The firm had revenue of $42.06 million during the quarter, compared to analyst estimates of $40.31 million. During the same quarter in the previous year, the business earned $0.01 EPS. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. Equities analysts anticipate that Vanda Pharmaceuticals Inc. will post ($0.47) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Rice Hall James & Associates LLC Increases Position in Vanda Pharmaceuticals Inc. (VNDA)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/16/rice-hall-james-associates-llc-increases-position-in-vanda-pharmaceuticals-inc-vnda.html.

VNDA has been the subject of a number of recent research reports. Piper Jaffray Companies reiterated an “overweight” rating and set a $23.00 price objective on shares of Vanda Pharmaceuticals in a research report on Tuesday, June 27th. HC Wainwright initiated coverage on Vanda Pharmaceuticals in a research report on Friday, May 26th. They set a “buy” rating and a $18.00 price objective for the company. Zacks Investment Research upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, June 14th. Oppenheimer Holdings, Inc. set a $21.00 price objective on Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. Finally, TheStreet upgraded Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Friday, May 12th. One research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $21.33.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.